RMD
Status-Quo-PlayerResMed
$230.26
+0.62%
as of 13 Apr
Power Core
ResMed's moat is the integration of a dominant installed device base with a proprietary cloud data ecosystem that creates compounding switching costs across patients, clinicians, and payers simultaneously.
Direction of Movement
Lateral With Upward Bias as Fundamentals Diverge From Narrative
ROC 200
-11.0%
RMD
ResMed
$230.26
+0.62%
as of 13 Apr
DCF Fair Value: $277.99
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
ResMed Inc. is a global medical technology company that develops, manufactures, and markets advanced medical devices and cloud-based software solutions for diagnosing, treating, and managing respiratory and sleep disorders. The company operates through two primary segments: Sleep and Breathing Health, and Residential Care Software. Its Sleep and Breathing Health division produces devices including CPAP machines, portable diagnostic tools like ApneaLink Air, masks, and accessories designed for sleep apnea and other respiratory conditions. ResMed's digital health ecosystem spans cloud-connected platforms that enable remote patient monitoring and telemedicine capabilities, providing recurring revenue opportunities through software services. The Residential Care Software segment serves long-term care facilities with specialized management solutions. With a global presence across multiple continents, ResMed addresses the growing healthcare demand for effective sleep and respiratory disorder treatments. The company combines medical device innovation with digital health integration, positioning itself as a leader in improving patient outcomes and supporting healthcare providers worldwide.